6-ketoprostaglandin-f1-alpha and Leukemia--Myeloid--Acute

In recent years, it is known that endothelial cells play an important role in the genesis of some diseases, but there are only few papers dealing with the role of endothelial cells in leukemia. In this study some of the active factors released by the endothelial cells in patients with acute leukemia such as von Willebrand factor, prostaglandin, fibronectin, tissue-type plasminogen activator and its inhibitor were determined. It was found that the levels of these factors changed significantly in patients with acute leukemia, as compared with those in normal controls, especially in cases with bleeding tendency and infection. The possible mechanism and the clinical significance were discussed.

Topics: 6-Ketoprostaglandin F1 alpha; Adolescent; Adult; Antigens; Endothelium, Vascular; Female; Fibronectins; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; von Willebrand Factor

Topics: 6-Ketoprostaglandin F1 alpha; Adolescent; Adult; Disseminated Intravascular Coagulation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thromboxane B2

To determine the effect of anti-neoplastic chemotherapy on the vascular system(s) of children with leukemia/lymphoma, urinary excretion of 6-keto-PGF1 alpha was measured by radioimmunoassay (RIA). In 4 patients receiving therapy, 6-keto-PGF1 alpha increased to a mean of 148 (range; 126-170)% during therapy, then returned to pre-treatment level 3-5 days later. In 18 long-term survivors who had completed therapy, 6-keto-PGF1 alpha was determined to be a mean of 275 (range; 52-905) ng/g creatinine, and in the healthy control children the mean was 146 (range; 71-348) ng/g creatinine. These results were contrary to our hypothesis that chemotherapy might cause a decreased synthesis of PGI2, a precursor of 6-keto-PGF1 alpha, and suggest that increased urinary 6-keto-PGF1 alpha reflects a vascular response to acute exposure to chemotherapeutic drugs and possible vascular damage due to long-term intensive chemotherapy in pediatric patients with leukemia/lymphoma.

Topics: 6-Ketoprostaglandin F1 alpha; Antineoplastic Combined Chemotherapy Protocols; Child; Female; Follow-Up Studies; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Prognosis; Radioimmunoassay; Reference Values